Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NextCell Pharma ABFRA:65G -5.84%42 Days Inventory is 20.25 as of Dec. 2025, which is 14% below its 10-year median of 23.51. GuruFocus rates FRA:65G with a GF Score™ of 42/100 and a GF Value™ of €0.06 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 637 Biotechnology companies, NextCell Pharma AB ranks better than 95.76% on this metric.
The historical rank and industry rank for NextCell Pharma AB's Days Inventory or its related term are showing as below:
FRA:65G'
s Days Inventory Range Over the Past 10 Years
Min: 16.02 Med: 23.51 Max: 32.09
Current: 20.31
During the past 11 years, NextCell Pharma AB's highest Days Inventory was 32.09. The lowest was 16.02. And the median was 23.51.
FRA:65G's Days Inventory is ranked better than 95.76% of 637
companies
in the Biotechnology industry
Industry Median: 183.16
vs FRA:65G: 20.31
NextCell Pharma AB's Days Inventory
increased
from Nov. 2024 (20.07) to Dec. 2025 (20.25).
It might indicate that NextCell Pharma AB's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
NextCell Pharma AB's Inventory Turnover for the
three
months ended in Dec. 2025 was 4.51.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
NextCell Pharma AB's Inventory-to-Revenue for the
three
months ended in Dec. 2025 was 0.24.
NextCell Pharma AB (FRA:65G) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
NextCell Pharma AB's Inventory Turnover for the
three
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
NextCell Pharma AB's Inventory to Revenue for the
three
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
NextCell Pharma AB Days Inventory Related Terms
NextCell Pharma AB Days Inventory Historical Data
* Premium members only.
The historical data trend for NextCell Pharma AB's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:65G vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, NextCell Pharma AB's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCell Pharma AB Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's Days Inventory distribution charts can be found below:
* The bar in red indicates where NextCell Pharma AB's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCell Pharma AB (FRA:65G) has a Days Inventory of 20.25 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on NextCell Pharma AB and its competitors. This is 14% below median its historical median of 23.51. Over the past decade, NextCell Pharma AB's Days Inventory has ranged from 16.02 to 32.09. According to the industry distribution chart, NextCell Pharma AB ranks #27 out of 637 companies in the Biotechnology industry, placing it in the top 4.2%.
Is NextCell Pharma AB's Days Inventory too high?
NextCell Pharma AB's current Days Inventory of 20.25 is 14% below median its 10-year median of 23.51. Over the past 10 years, this metric has ranged from a low of 16.02 to a high of 32.09. The Biotechnology industry median Days Inventory is 183.16. NextCell Pharma AB's value of 20.25 is 88.9% below this industry median. Based on the distribution chart, NextCell Pharma AB ranks #27 out of 637 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, NextCell Pharma AB has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, NextCell Pharma AB ranks #27 out of 637 companies for Days Inventory. This places NextCell Pharma AB in the top 4% of its industry — outperforming the majority of peers. The industry median Days Inventory is 183.16. NextCell Pharma AB's value of 20.25 is 88.9% below this benchmark. Historically, NextCell Pharma AB's own Days Inventory has ranged from 16.02 to 32.09 over the past decade. While the company's 10-year median is 23.51 vs. the industry median of 183.16, NextCell Pharma AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.16, based on 637 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NextCell Pharma AB's current Days Inventory of 20.25 is 88.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on NextCell Pharma AB and its competitors. For the Biotechnology industry, the median Days Inventory is 183.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NextCell Pharma AB's current Days Inventory is 20.25, which is 14% below median its own 10-year median of 23.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (FRA:65G) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.06, compared to a current price of €0.07 — trading 21% above its estimated fair value. The current Days Inventory is 20.25, which is 14% below median its 10-year median of 23.51 and 88.9% below the Biotechnology industry median of 183.16. NextCell Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For NextCell Pharma AB (FRA:65G), the current Days Inventory is 20.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NextCell Pharma AB (FRA:65G) Overvalued in 2026?
Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued.
The current stock price of €0.07 is trading 21% above its estimated GF Value™ of €0.06.
GuruFocus considers NextCell Pharma AB to be Modestly Overvalued.
Key valuation signals for FRA:65G:
Days Inventory: 20.25 (14% below median its 10-year median of 23.51)
GF Value™: €0.06 vs. price of €0.07 (21% above fair value)
Industry Position: 88.9% below the Biotechnology median (#27 of 637)
No single metric tells the full story. See the FRA:65G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score
Get the complete analysis for FRA:65G
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:65G has been successfully added to your 
